Conclusions:
KRAS mutations are relatively common in lung adenocarcinoma with KRAS G12C being the most common variant. • While overall adenocarcinoma carries higher prevalence of KRAS mutation, no significant difference in mutation types were seen. • TMB high (>10) was significantly different across KRAS mutation types. • KRAS G12C was associated with the highest rate of PD-L1 expression. • Different KRAS mutations have unique co-occurring mutations and a different genomic landscape. • The clinical relevance in the differences of KRAS mutations subtypes warrants further investigation in the context of therapeutic intervention.